What SEC filings does Relmada Therapeutics, Inc. submit to the SEC?

Relmada Therapeutics, Inc. (RLMD) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about RLMD?

A Form 4 for RLMD discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Relmada Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for RLMD?

The 10-K is Relmada Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all RLMD SEC filings directly on EDGAR?

You can view all historical Relmada Therapeutics, Inc. filings on the SEC EDGAR company page for RLMD. Each filing card on this page links directly to the original SEC document.

How often does Relmada Therapeutics, Inc. file with the SEC?

Relmada Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling RLMD shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

RLMD SEC Filing News — Relmada Therapeutics, Inc.

Latest SEC filings for Relmada Therapeutics, Inc. (RLMD) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-11.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessiv…

Sector: Healthcare Industry: Biotechnology Market Cap: $337.1M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for RLMD currently lean bullish. Of the 12 displayed SEC filing records, 2 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 2 insider transactions (Form 4) in this period.

RLMD Filing Activity Snapshot 2026-03-09 — 2026-09-11

Insider Transactions (Form 4)

2 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$844.0K

Shenouda Maged (Chief Financial Officer) · 2026-09-11

200,000 shares · Form 4

Insider Transactions 2 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 2 filings in this group are Form 4s for Relmada Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 2 insider filings shown, the breakdown is 2 open-market purchase. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market purchase ×2: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Open-market purchase Insider Buying 2026-09-11

RLMD insider Shenouda Maged (Chief Financial Officer) bought 200,000 shares (~$844.0K)

Shenouda Maged, listed as Chief Financial Officer at RELMADA THERAPEUTICS, INC., reported an open-market purchase of 200,000 RLMD shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	120,200	$4.20	$504.8K
`P`	Open-market purchase	79,800	$4.25	$339.1K

Filing: Form 4 (Insider Transaction) Insider: Shenouda Maged (Chief Financial Officer) Shares: 200,000 Est. Value: $844.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-09-11

RLMD insider TRAVERSA SERGIO (Director, Chief Executive Officer) bought 200,000 shares (~$828.0K)

TRAVERSA SERGIO, listed as Director, Chief Executive Officer at RELMADA THERAPEUTICS, INC., reported an open-market purchase of 200,000 RLMD shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	100,000	$4.18	$418.0K
`P`	Open-market purchase	100,000	$4.10	$410.0K

Filing: Form 4 (Insider Transaction) Insider: TRAVERSA SERGIO (Director, Chief Executive Officer) Shares: 200,000 Est. Value: $828.0K

View on SEC EDGAR → Open Filing Document →

Material Events 7 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 7 in this period for Relmada Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-08

RLMD filed 8-K — material company event

RELMADA THERAPEUTICS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.